Clinical Trial Detail

NCT ID NCT04128748
Title Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

CPX-351 + Quizartinib

Age Groups: adult senior

No variant requirements are available.